TRAIL Monoclonal antibody

TRAIL Monoclonal Antibody for IHC, WB,ELISA

Host / Isotype

Mouse / IgG1

Reactivity

Human and More (1)

Applications

WB, IHC,ELISA

Conjugate

Unconjugated

CloneNo.

1B9B4

Cat no : 66756-1-Ig

Synonyms

Apo 2 ligand, Apo 2L, APO2L, CD253, Protein TRAIL, TL2, TNFSF10, TRAIL



Tested Applications

Positive WB detected inhuman milk tissue
Positive IHC detected inhuman tonsillitis tissue, human prostate cancer tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:2000
Immunohistochemistry (IHC)IHC : 1:50-1:500
Sample-dependent, check data in validation data gallery

Published Applications

WBSee 1 publications below

Product Information

66756-1-Ig targets TRAIL in WB, IHC,ELISA applications and shows reactivity with Human samples.

Tested Reactivity Human
Cited Reactivity human
Host / Isotype Mouse / IgG1
Class Monoclonal
Type Antibody
Immunogen TRAIL fusion protein Ag25746
Full Name tumor necrosis factor (ligand) superfamily, member 10
Calculated molecular weight 281 aa, 33 kDa
Observed molecular weight 28-30 kDa
GenBank accession numberBC032722
Gene symbol TNFSF10
Gene ID (NCBI) 8743
Conjugate Unconjugated
Form Liquid
Purification Method Protein G purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

TNFSF10/TRAIL (tumor necrosis factor superfamily member 10) is a typical death ligand expressed on natural killer cells and cytotoxic T lymphocytes. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. TNFSF10 induces apoptotic cell death in cancer by binding to its functional death receptors, death receptor (DR) 4 (TNFRSF10A/TRAIL-R1) and DR5 (TNFRSF10B/TRAIL-R2) to activate the extrinsic apoptosis pathway. TRAIL also activates c-Jun N-terminal kinase (MAPK8/JNK) and the transcription factor nuclear factor-κB (NFκB). The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3.

Protocols

Product Specific Protocols
WB protocol for TRAIL antibody 66756-1-IgDownload protocol
IHC protocol for TRAIL antibody 66756-1-IgDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
human

Adv Healthc Mater

TRAIL-Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582).

Authors - Huan Hou
humanWB

Cancers (Basel)

Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib.

Authors - Changhong Ke